Adeno-Associated Viral Vectors

AAV Vector Use in In Vivo Vascular Gene Transfer Reported

Published in Blood Weekly, April 21st, 1997

Targeted Genetics Corp., Seattle, Washington, reported positive research results that indicate its adeno-associated viral (AAV) vector delivery system may be useful in a gene therapy product for the treatment of cardiovascular diseases.

In their paper published in the April 1997 issue of Circulation Research, researchers at Targeted Genetics, led by Carmel M. Lynch, Ph.D., and the Bowman Gray School of Medicine at Wake Forest University, led by Randolph L. Geary, Ph.D., reported the successful introduction of a recombinant AAV (rAAV) into the blood vessel cells of a variety of species, including primates and humans.

"We have demonstrated the utility...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (1997-04-21)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry